Author: Michael A. Robinson, Money Morning

Even though it’s been one of the fastest-growing medical firms of the last decade, it shows no signs of slowing down…

In short, the company’s new product could have a solid, long-term effect on the stock…

It’s a fixture in our Roadmap to Marijuana Millions legal cannabis portfolio. It gets you low-risk entry into the legal cannabis sector and a respectable 2.14% dividend yield. It’s a stock to buy now and build out on dips.

It’s already delivered peak returns of more than 1,100% over the past three years, and I think there’s every reason for it to happen all over again…